Researchers are optimistic about climate change solutions.

Researchers from UC Davis and UC Cooperative Extension are testing a new method for capturing water by diverting it from rivers into Central Valley canals.

Guess what? You’re only 10 percent human — the rest of you is made up of bacteria, viruses, fungi and other microbes. Science Today talks with UC San Diego Chancellor Pradeep Khosla and professor Rob Knight about a new Microbiome and Microbial Sciences Initiative that will advance the study of microbiomes found in the gut and everywhere else on Earth.

A genetic engineering technique raises hopes for eliminating diseases, such as malaria. But it is also sparking fears of unintended consequences if delicately balanced ecosystems are disrupted.

UC Berkeley's roach-inspired robot is but one of a number of ways the much-maligned insect is influencing research.

UC and other researchers say they are getting closer to giving people a crucial minute or two of warning before a significant temblor.

A UC Davis study finds polygyny — one husband, more than one wife — might benefit some families, especially those living in countries where food insecurity is an issue.

A new study, featuring research out of UC Irvine, finds that older female workers face a hiring disadvantage in certain fields, which has serious consequences for their retirement security.

UCLA's AirForU app lets users check for unsafe smog levels anywhere in the U.S. — especially useful for asthmatics or others with respiratory problems.

By revealing the complex science behind plant growth, Lawrence Berkeley National Laboratory researchers hope to replace food deserts — low-income urban areas that lack access to affordable, fresh food — with options to purchase local, sustainably produced vegetables at or below conventional market prices, grown using drastically less water and fertilizer than conventional agriculture. Read more

Hepatitis B vaccine, the nicotine patch, the tasty Camarosa strawberry: Those patented innovations have earned UC, and the faculty who developed them, more than $500 million.

Late-phase trials found that the drug greatly reduced symptoms for progressive multiple sclerosis as well as a more common form of the disease.